Brokers Offer Predictions for SLDB FY2027 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - HC Wainwright issued their FY2027 earnings estimates for shares of Solid Biosciences in a report issued on Monday, July 14th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($1.70) for the year. HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences' FY2028 earnings at ($0.74) EPS and FY2029 earnings at $1.10 EPS.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.06).

Other equities analysts have also recently issued research reports about the stock. Chardan Capital lowered their price objective on shares of Solid Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Wedbush lowered their price objective on shares of Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating on the stock in a research note on Friday, May 16th. Barclays decreased their target price on shares of Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating for the company in a report on Friday, May 16th. JMP Securities reiterated a "market outperform" rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Friday, June 6th. Finally, Citigroup initiated coverage on shares of Solid Biosciences in a report on Thursday, June 26th. They issued a "buy" rating and a $14.00 target price for the company. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $15.10.

Solid Biosciences Price Performance

Shares of SLDB traded up $0.60 during mid-day trading on Wednesday, hitting $6.39. The company's stock had a trading volume of 3,438,857 shares, compared to its average volume of 1,226,917. The firm has a 50-day moving average price of $4.26 and a 200 day moving average price of $4.01. The stock has a market capitalization of $495.32 million, a price-to-earnings ratio of -2.14 and a beta of 2.34. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $10.37.

Institutional Trading of Solid Biosciences

Institutional investors have recently made changes to their positions in the stock. CWM LLC lifted its stake in Solid Biosciences by 15,188.5% in the first quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after acquiring an additional 7,898 shares during the last quarter. Corton Capital Inc. acquired a new stake in Solid Biosciences in the fourth quarter valued at approximately $41,000. Ground Swell Capital LLC acquired a new stake in Solid Biosciences in the first quarter valued at approximately $42,000. Invesco Ltd. acquired a new stake in Solid Biosciences in the fourth quarter valued at approximately $49,000. Finally, Sei Investments Co. acquired a new stake in Solid Biosciences in the fourth quarter valued at approximately $52,000. 81.46% of the stock is currently owned by institutional investors and hedge funds.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.